Trial Profile
A 20-week Study Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients Uncontrolled on NPH Insulin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Aug 2017
Price :
$35
*
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 01 Aug 2017 Primary endpoint (Change in HbA1c From Baseline) has been met, according to the results published in the Diabetes Therapy.
- 01 Aug 2017 Results published in the Diabetes Therapy
- 15 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.